{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:11:01Z","timestamp":1760127061734,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Pre-eclampsia is a major public health issue. Current screening methods are based on maternal characteristics and medical history, but complex predictive models combining different clinical and biochemical markers have been proposed. However, although their accuracy is high, the implementation of these models in clinical practice is not always feasible, especially in low- and middle-resource settings. CA-125 is a tumoral marker, accessible and cheap, with proven potential as a severity marker in the third trimester of pregnancy in pre-eclamptic women. Assessment of its use as a first-trimester marker is necessary. Methods: This observational study involved fifty pregnant women between 11 and 14 weeks of pregnancy. Clinical and biochemical markers (PAPP-A), known for their value in pre-eclampsia screening, were recorded for every patient as well as first-trimester value of CA-125 and third-trimester data regarding blood pressure and pregnancy outcome. Results: No statistical correlation between CA-125 and first-trimester markers was observed except with PAPP-A, with which it exhibited a positive correlation. Additionally, no correlation was made between it and third-trimester blood pressure or pregnancy outcomes. Conclusions: CA-125 first-trimester values do not represent a valuable marker for pre-eclampsia screening. Further research on identifying an accessible and cheap marker to improve pre-eclampsia screening in low- and middle-income settings is needed.<\/jats:p>","DOI":"10.3390\/medicina59050891","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:04:48Z","timestamp":1683518688000},"page":"891","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia"],"prefix":"10.3390","volume":"59","author":[{"given":"Oana","family":"Balint","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Medicine and Pharmacy \u201cVictor Babes\u201d, 300041 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1355-3790","authenticated-orcid":false,"given":"Cristina","family":"Secosan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Medicine and Pharmacy \u201cVictor Babes\u201d, 300041 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurentiu","family":"Pirtea","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Medicine and Pharmacy \u201cVictor Babes\u201d, 300041 Timi\u0219oara, Romania"},{"name":"Emergency Clinical City Hospital Timi\u0219oara, Obstetrics-Gynecology Clinic, 300231 Timi\u0219oara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jri.2019.07.004","article-title":"The Two-Stage Placental Model of Preeclampsia: An Update","volume":"134\u2013135","author":"Staff","year":"2019","journal-title":"J. Reprod. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) Initiative on Pre-eclampsia: A Pragmatic Guide for First-trimester Screening and Prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int. J. Gynecol. Obs."},{"key":"ref_3","unstructured":"(2010). National Collaborating Centre for Women\u2019s and Children\u2019s Health (UK) Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy, RCOG Press. National Institute for Health and Clinical Excellence: Guidance."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/uog.17455","article-title":"Multicenter Screening for Pre-Eclampsia by Maternal Factors and Biomarkers at 11\u201313 Weeks\u2019 Gestation: Comparison with NICE Guidelines and ACOG Recommendations","volume":"49","author":"Wright","year":"2017","journal-title":"Ultrasound Obs. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","article-title":"The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects","volume":"Volume 867","author":"Scatena","year":"2015","journal-title":"Advances in Cancer Biomarkers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.ph.57.030195.003135","article-title":"Epithelial Mucin Genes","volume":"57","author":"Gendler","year":"1995","journal-title":"Annu. Rev. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","article-title":"Roles of CA125 in Diagnosis, Prediction, and Oncogenesis of Ovarian Cancer","volume":"1875","author":"Zhang","year":"2021","journal-title":"Biochim. Biophys. Acta (BBA) Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0002-9378(91)90687-M","article-title":"CA 125 Levels in Abruptio Placentae","volume":"164","author":"Witt","year":"1991","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0015-0282(99)00554-3","article-title":"Differentiating Tubal Abortion from Viable Ectopic Pregnancy with Serum CA-125 and Beta-Human Chorionic Gonadotropin Determinations","volume":"73","author":"Predanic","year":"2000","journal-title":"Fertil. Steril."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1447-0756.2006.00424.x","article-title":"CA-125 Levels in Ruptured and Unruptured Tubal Ectopic Pregnancies","volume":"32","author":"Malatyalioglu","year":"2006","journal-title":"J. Obs. Gynaecol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/10641950802601187","article-title":"CA-125 and CRP Are Elevated in Preeclampsia","volume":"28","author":"Cebesoy","year":"2009","journal-title":"Hypertens. Pregnancy"},{"key":"ref_12","first-page":"29","article-title":"Maternal Serum CA-125 Level Is Elevated in Severe Preeclampsia","volume":"4","author":"Karaman","year":"2014","journal-title":"Pregnancy Hypertens. Int. J. Women\u2019s Cardiovasc. Health"},{"key":"ref_13","first-page":"416","article-title":"Determination of Cancer Antigen-125 Level and Its Association with Preeclampsia among Sudanese Women","volume":"11","author":"Karrar","year":"2020","journal-title":"Ann. Clin. Anal. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00404-010-1736-2","article-title":"Serum Concentrations of CA-125 in Normal and Preeclamptic Pregnancies","volume":"284","author":"Ozat","year":"2011","journal-title":"Arch. Gynecol. Obs."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Balint, O., Secosan, C., and Pirtea, L. (2022). Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia. Healthcare, 10.","DOI":"10.3390\/healthcare10122474"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e13380","DOI":"10.1111\/ijcp.13380","article-title":"Serum CA-125 Levels in Preeclampsia: A Systematic Review and Meta-analysis","volume":"73","author":"Bellos","year":"2019","journal-title":"Int. J. Clin. Pract."},{"key":"ref_17","first-page":"S0002937820307419","article-title":"First Trimester Preeclampsia Screening and Prediction","volume":"226","author":"Chaemsaithong","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"(2020). Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet. Gynecol., 135, e237.","DOI":"10.1097\/AOG.0000000000003891"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pd.1970151305","article-title":"First Trimester Serum Screening for down\u2019s Syndrome","volume":"15","author":"Wald","year":"1995","journal-title":"Prenat. Diagn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-800094-6.00005-4","article-title":"Pregnancy-Associated Plasma Protein A (PAPP-A) and Preeclampsia","volume":"Volume 63","author":"Zima","year":"2014","journal-title":"Advances in Clinical Chemistry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/uog.6280","article-title":"First-Trimester Maternal Serum Pregnancy-Associated Plasma Protein-A and Pre-Eclampsia","volume":"33","author":"Poon","year":"2009","journal-title":"Ultrasound Obs. Gynecol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/jhh.2017.61","article-title":"Placental Growth Factor and Pre-Eclampsia","volume":"31","author":"Chau","year":"2017","journal-title":"J. Hum. Hypertens."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.placenta.2009.08.003","article-title":"Differential Regulation of Human PlGF Gene Expression in Trophoblast and Nontrophoblast Cells by Oxygen Tension","volume":"30","author":"Gobble","year":"2009","journal-title":"Placenta"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating Angiogenic Factors and the Risk of Preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/uog.6244","article-title":"Maternal Serum Placental Growth Factor at 11 + 0 to 13 + 6 Weeks of Gestation in the Prediction of Pre-Eclampsia","volume":"32","author":"Akolekar","year":"2008","journal-title":"Ultrasound Obs. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhong, Y., Zhu, F., and Ding, Y. (2015). Serum Screening in First Trimester to Predict Pre-Eclampsia, Small for Gestational Age and Preterm Delivery: Systematic Review and Meta-Analysis. BMC Pregnancy Childbirth, 15.","DOI":"10.1186\/s12884-015-0608-y"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/1471-0528.15042","article-title":"Angiogenic Factors: Potential to Change Clinical Practice in Pre-Eclampsia?","volume":"125","author":"Cerdeira","year":"2018","journal-title":"BJOG Int. J. Obs. Gynaecol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/HYPERTENSIONAHA.113.01787","article-title":"New Gestational Phase\u2013Specific Cutoff Values for the Use of the Soluble Fms-Like Tyrosine Kinase-1\/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia","volume":"63","author":"Verlohren","year":"2014","journal-title":"Hypertension"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive Value of the SFlt-1:PlGF Ratio in Women with Suspected Preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(15)00070-7","article-title":"Pre-Eclampsia","volume":"387","author":"Mol","year":"2016","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice","volume":"72","author":"Brown","year":"2018","journal-title":"Hypertension"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/uog.21869","article-title":"From First-trimester Screening to Risk Stratification of Evolving Pre-eclampsia in Second and Third Trimesters of Pregnancy: Comprehensive Approach","volume":"55","author":"Poon","year":"2020","journal-title":"Ultrasound Obs. Gynecol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/uog.18816","article-title":"ASPRE Trial: Performance of Screening for Preterm Pre-Eclampsia: ASPRE Trial Screening Performance","volume":"50","author":"Rolnik","year":"2017","journal-title":"Ultrasound Obs. Gynecol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/uog.19039","article-title":"Comparison of Diagnostic Accuracy of Early Screening for Pre-Eclampsia by NICE Guidelines and a Method Combining Maternal Factors and Biomarkers: Results of SPREE: First-Trimester Screening for Pre-Eclampsia","volume":"51","author":"Tan","year":"2018","journal-title":"Ultrasound Obs. Gynecol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1097\/AOG.0000000000002708","article-title":"Low-Dose Aspirin Use During Pregnancy","volume":"132","author":"Porter","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"685.e1","DOI":"10.1016\/j.ajog.2017.08.110","article-title":"Aspirin for Evidence-Based Preeclampsia Prevention Trial: Influence of Compliance on Beneficial Effect of Aspirin in Prevention of Preterm Preeclampsia","volume":"217","author":"Wright","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/14767058.2017.1387532","article-title":"Impact of Early Supplementation with Low-Dose Aspirin on Functional First Trimester Parameters in Low-Risk Pregnancies","volume":"32","author":"Zvanca","year":"2019","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/AOG.0000000000003413","article-title":"Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis","volume":"134","author":"Mallampati","year":"2019","journal-title":"Obstet. Gynecol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000053903","article-title":"Maternal Serum CA125 and CA15-3 Antigen Levels in Normal and Pathological Pregnancy","volume":"16","author":"Bon","year":"2001","journal-title":"Fetal Diagn."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00404-011-2025-4","article-title":"Serum Concentrations of CA 125, CA 15-3, CA 19-9 and CEA in Normal Pregnancy: A Longitudinal Study","volume":"285","author":"Ercan","year":"2012","journal-title":"Arch. Gynecol. Obs."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5001\/omj.2012.26","article-title":"The Values of CA-125, Progesterone, \u00df-HCG and Estradiol in the Early Prediction of Ectopic Pregnancy","volume":"27","year":"2012","journal-title":"Oman Med. J."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/891\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:30:15Z","timestamp":1760124615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["medicina59050891"],"URL":"https:\/\/doi.org\/10.3390\/medicina59050891","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,5,6]]}}}